Brokerages Set Genmab A/S (NASDAQ:GMAB) Price Target at $42.17

Genmab A/S (NASDAQ:GMAB) has been given a consensus recommendation of “Moderate Buy” by the twelve research firms that are covering the firm, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation, seven have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $42.17.

A number of research analysts have recently commented on GMAB shares. Leerink Partnrs raised shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 13th. HC Wainwright reissued a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a research report on Thursday, January 23rd. Sanford C. Bernstein raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, December 20th. Leerink Partners raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 target price on the stock in a research report on Thursday, February 13th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $48.00 price target (up from $46.00) on shares of Genmab A/S in a report on Friday, November 8th.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. increased its stake in shares of Genmab A/S by 94.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 26,104 shares of the company’s stock valued at $636,000 after buying an additional 12,654 shares in the last quarter. HighTower Advisors LLC acquired a new stake in shares of Genmab A/S in the third quarter valued at $273,000. Verition Fund Management LLC acquired a new stake in shares of Genmab A/S in the third quarter valued at $709,000. AIMZ Investment Advisors LLC acquired a new stake in shares of Genmab A/S in the fourth quarter valued at $3,525,000. Finally, Natixis Advisors LLC increased its stake in shares of Genmab A/S by 29.8% in the third quarter. Natixis Advisors LLC now owns 206,563 shares of the company’s stock valued at $5,036,000 after buying an additional 47,437 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Stock Performance

GMAB stock opened at $24.14 on Wednesday. Genmab A/S has a one year low of $18.64 and a one year high of $31.88. The stock has a market capitalization of $15.98 billion, a PE ratio of 13.87, a price-to-earnings-growth ratio of 2.65 and a beta of 0.98. The company has a fifty day moving average of $21.28 and a 200-day moving average of $22.69.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, beating the consensus estimate of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. Equities analysts forecast that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.